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Abstract
Background: In rheumatoid arthritis (RA), cardiovascular risk is associated with paradoxical reductions in total
cholesterol, low density lipoprotein-cholesterol (LDL-C), and high density lipoprotein-cholesterol (HDL-C).
Concentrations of small LDL (LDL-P) and HDL (HDL-P) particles are also reduced with increased inflammation
and disease activity in RA patients. Here we sought to identify which measure(s) of inflammation, disease activity
and cardiometabolic risk contribute most to the RA-associated lipoprotein profile.
Methods: NMR lipoprotein measurements were obtained for individuals with RA (n = 50) and age-, gender-, and
body mass index (BMI)-matched controls (n = 39). Groups were compared using 39 matched pairs with 11
additional subjects used in RA only analyses. Among RA patients, relationships were determined for lipoprotein
parameters with measures of disease activity, disability, pain, inflammation, body composition, insulin sensitivity
and exercise. Percentage of time spent in basal activity (<1 metabolic equivalent) and exercise (≥3 metabolic
equivalents) were objectively-determined.
Results: Subjects with RA had fewer total and small LDL-P as well as larger LDL and HDL size (P < 0.05). Among RA
patients, pain and disability were associated with fewer small HDL-P (P < 0.05), while interleukin (IL)-6, IL-18, and
TNF-α were associated with LDL size (P < 0.05). BMI, waist circumference, abdominal visceral adiposity and insulin
resistance were associated with more total and small LDL-P, fewer large HDL-P, and a reduction in HDL size
(P < 0.05). Most similar to the RA lipoprotein profile, more basal activity (minimal physical activity) and less exercise
time were associated with fewer small LDL-P and total and small HDL-P (P < 0.05).
Conclusions: The RA-associated lipoprotein profile is associated with a lack of physical activity.
As this was a cross-sectional investigation and not an intervention and was performed from 2008–13, this study
was not registered in clinicaltrials.gov.
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Background
Patients with rheumatoid arthritis (RA), a chronic inflam-
matory disease, have a 2- to 3-fold increased risk of
cardiovascular disease (CVD) [1–4]. This has been attrib-
uted to disease-associated chronic inflammation, physical
inactivity, increased adiposity, insulin resistance, and al-
tered lipid profiles [5, 6]. Despite the increased CVD risk,
RA patients often present with reduced total cholesterol,
low density lipoprotein cholesterol (LDL-C) and high
density lipoprotein cholesterol (HDL-C), which is opposite
of the lipid profile typically observed in subjects at high
risk of CVD [7–9]. Hence, the relationship between high
CVD risk and lower cholesterol levels in RA patients has
been referred to as the “lipid paradox.” [7–9].
Efforts to better understand the “lipid paradox” have
included the measurement of lipoprotein particles via
nuclear magnetic resonance spectroscopy (NMR) in pa-
tients with RA [10]. Compared to controls, RA patients
have fewer small LDL (LDL-P) and small HDL (HDL-P)
particles [10]. Moreover, small HDL-P are inversely
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calcification in RA patients [10]. In active RA, HDL
particles contain pro-inflammatory proteins such as
serum amyloid A and fibrinogen which often replace
anti-inflammatory and anti-oxidant molecules, which
alters their function [11]. All in all, inflammation medi-
ates alterations in HDL particle size and function that
may contribute to the increased CVD observed in RA
patients [12]. Furthermore, after anti-inflammatory
therapy, total cholesterol, LDL-C, HDL-C, HDL-P
levels increase [13]. Such increases have been attributed
to reduced inflammation and cholesterol ester catabol-
ism leading to an increase in lipoprotein cholesteryl
ester levels [13]. While increased cholesterol levels are
often associated with increased CVD risk, in the con-
text of chronic inflammatory disease increased circulat-
ing cholesterol may be a reflection of the reduced
inflammation and an accompanied reduction in CVD
risk [13, 14].
Unfortunately, the changes observed in circulating
lipids and lipoproteins in RA patients are complex as
many factors besides inflammation contribute to the
overall picture. For example, there are known alterations
in cholesterol and lipoproteins that occur in subjects
who are overweight with metabolic syndrome and/or
type 2 diabetes. These include reductions in HDL-C,
large HDL-P and large LDL-P and an increase in triglyc-
erides, small LDL-P and small HDL-P, while LDL-C
levels often remain in the normal range. In contrast,
exercise often reverses these changes. High amounts of
exercise lead to decreased small LDL-P and total LDL-P
and increased large HDL-P, HDL-C as well as HDL and
LDL size [15]. Patients with RA are often overweight,
especially when regular physical activity is impaired by
disease activity and joint damage. Therefore, disease
activity, physical activity and metabolic syndrome risk
factors such as body mass index (BMI), waist circumfer-
ence and insulin resistance, may confound the effects of
inflammation on cholesterol and lipoprotein parameters
in patients with RA.
In a recent study in established and treated RA pa-
tients, we found that traditional metabolic risk factors
such as excess adiposity played a more prominent role
in predicting skeletal muscle insulin sensitivity than
systemic inflammation or other disease-related fac-
tors.[16] However, we hypothesized that the changes
observed in the “lipid paradox” are less related to
metabolic syndrome risk factors and more related to
lack of physical activity as a result of increased disease
activity, pain and inflammation. To test this hypoth-
esis we looked at the associations between NMR lipo-
protein parameters and various measures of disease
activity, inflammation, body composition, insulin
sensitivity and physical activity (basal activity vs.
exercise).
Methods
Participants and design
The study design and procedures have been previously
reported [16]. Briefly, this was a cross-sectional com-
parison of insulin sensitivity between persons with RA
and age- (+/− three years), gender-, race-, and BMI
(+/− 3 kg/m2) -matched controls (n = 39 each). An
additional 11 subjects with RA without a match were
include in RA-only analyses. Persons with RA were ei-
ther seropositive or had erosions on radiographs, met
1987 American College of Rheumatology criteria for
RA [17], had no medication changes in the last three
months, and were using stable doses of prednisone of
5 mg or less per day. Exclusions were known diabetes
mellitus or CVD. Five persons with RA and two controls
were using HMG CoA reductase inhibitors (statins); find-
ings were not altered substantially when these persons
were excluded from analyses. The study was in compli-
ance with the Helsinki Declaration and was approved by
the Duke University Medical Center Institutional Review
Board (#7701).
Assessments
Physical examinations and questionnaires assessed an-
thropometrics, disease activity, pain, and disability [16].
Insulin sensitivity was calculated from glucose and insulin
concentrations during a frequently sampled intravenous
glucose tolerance test [16]. Fasting concentrations of in-
flammatory cytokines were measured using ELISAs [16].
Abdominal and thigh adipose depots were measured using
abdominal and thigh CT scans. Physical activity was
measured using seven days of accelerometry (RT3,
Stayhealthy, Inc., Monrovia, CA) [16, 18]. Data were ex-
cluded from analyses as follows: nonwear time defined
as 90 consecutive minutes of zero activity data; days
with less than 10 h of data; participants with less than
four (10-h) days. Physical activity analyses included 41
RA participants. Basal activity was defined as less than
one metabolic equivalent, the predicted amount of oxy-
gen consumed while sitting at rest [16]. Exercise was
defined as the combination of moderate, high, and very
high intensity activity or greater than or equal to 3 total
metabolic equivalents [16].
Lipid and lipoprotein measurements
NMR spectra were acquired from EDTA plasma sam-
ples as previously described for the NMR LipoProfile®
(lipoprotein particle) test at LipoScience, Inc. (now
LabCorp-Raleigh, NC) using the LipoProfile-3 algo-
rithm [19]. Mean VLDL, LDL and HDL particle sizes
are weighted averages derived from the sum of the
diameter of each subclass multiplied by its relative mass
percentage. The NMR Profiler platform is comprised of
a 9.4 T (400 MHz 1H frequency) spectrometer (Bruker
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Biospin) with an integrated fluidics sample delivery sys-
tem. Total cholesterol, triglycerides, LDL-C and HDL-
C were measured using standard automated methods.
Statistical analyses
Total cholesterol and LDL-C demonstrated a normal dis-
tribution confirmed with Kolmogorov-Smirnov Goodness
of Fit testing. Triglycerides, HDL-C, inflammatory
markers (high sensitivity C-reactive protein [hsCRP],
interleukin [IL]-1β, IL-6, IL-18, tumor necrosis factor
[TNF]-α), and lipoproteins were logarithmically trans-
formed prior to group comparisons. RA and controls (n =
39 each) were compared using mixed models, which
accounted for the repeated measure of matched partici-
pants. Bivariate associations were assessed with Spearman
correlations. Lipoprotein particle modeling was performed
with general linear models. All analyses were performed in
SAS (Version 9.4, Cary, NC). A priori levels of significance
were P < 0.1 for interactions and P < 0.05 for all other
analyses.
Results
Lipoprotein profile in subjects with RA
While triglycerides and HDL-C did not differ between RA
and controls, both total cholesterol and LDL-C were lower
in persons with RA (Table 1; P < 0.05 for both). For NMR-
measured lipoproteins as compared to controls, RA had
lower concentrations of both total LDL-P and small LDL-
P, with a larger mean LDL particle size (Table 1; P < 0.05
for all). While total HDL-P concentrations were similar to
controls, RA had a larger mean HDL particle size (Table 1;
P < 0.05 for all).
Lipoprotein particle associations with inflammation, pain,
and disability in RA
In persons with RA, greater concentrations of the inflam-
matory cytokines, IL-6, IL-18, and TNF-α, were associated
with reduced LDL particle size, (r = −0.31; r = −0.33; r =
−0.28; P < 0.05 for all). Medium HDL-P had an inverse as-
sociation with TNF-α (r = −0.31; P < 0.05). Inflammatory
cytokines were not significantly related to small HDL-P;
although increased pain and disability were associated
with fewer small HDL-P (r = −0.42; r = −0.37; P < 0.05 for
both).
Lipoprotein associations with body composition and
insulin action in RA
In persons with RA, lipoproteins and lipoprotein choles-
terol levels were associated with a number of measures of
cardiometabolic risk (Table 2). For LDL, concentrations of
both total LDL-P and small LDL-P were associated with
greater BMI, waist circumference, abdominal visceral adi-
posity, homeostasis model assessment of insulin resistance
[HOMA-IR], and fasting insulin (Table 2; P < 0.05 for all).
LDL-size was associated with insulin sensitivity and in-
versely associated with HOMA-IR and fasting insulin
(Table 2; P < 0.05 for all). For HDL, total HDL-P was
associated with insulin sensitivity while small HDL-P
was associated with waist circumference (Table 2; P < 0.05
for both). Large HDL-P and HDL-size were inversely cor-
related with BMI, waist circumference, abdominal visceral
adiposity, HOMA-IR and fasting insulin (Table 2; P < 0.05
for all). Medium HDL-P was inversely associated with
fasting insulin. LDL-C was associated with BMI, abdom-
inal visceral adiposity and fasting insulin while HDL-C
was associated with insulin sensitivity and inversely associ-
ated with waist circumference, HOMA-IR and fasting
insulin (Table 2; P < 0.05 for all). None of the lipoprotein
Table 1 Patient demographic and clinical characteristics
RA n = 50 Controls n = 39
Age (yrs) 55.4 ± 12.8 52.1 ± 11.4
Gender-Female 35 (70%) 27 (69%)
Race-
Pacific Islander 1 (2%) 0 (0%)
African American 14 (28%) 12 (31%)
Caucasian 35 (70%) 27 (69%)
Body mass index (kg/m2) 30.5 ± 7.5 29.0 ± 5.3
Waist circumference (cm) 95.3 ± 16.7 92.1 ± 13.3
Disability (HAQ-DI) 0.7 ± 0.7 0 ± 0
Disease Activity (DAS-28) 3.0 ± 1.4 n/a
hsCRP (mg/L) 3.8 ± 4.8† 2.0 ± 2.8
Basal activity (% min/week) 91.2 ± 6.0 88.8 ± 6.1
Exercise (% min/week) 1.1 ± 1.5 1.5 ± 1.3
Total cholesterol (mg/dl) 176.6 ± 30.7† 185.9 ± 32.3
LDL-cholesterol (mg/dl) 105.0 ± 24.7† 117.2 ± 26.4
HDL-cholesterol (mg/dl) 53.7 ± 1.3 49.2 ± 1.3
Triglycerides (mg/dl) 93.6 ± 1.6 96.6 ± 1.5
LDL Particles – Total (nmol/L) 965.1 ± 1.3† 1117.6 ± 1.4
Large LDL Particles (nmol/L) 363.0 ± 1.8 363.1 ± 1.6
Small LDL Particles (nmol/L) 386.2 ± 2.1† 521.2 ± 2.0
LDL Particle Size (nm) 20.9 ± 1.0† 20.7 ± 1.0
HDL Particles – Total (μmol/L) 29.1 ± 1.2 29.3 ± 1.2
Large HDL Particles (μmol/L) 4.9 ± 1.8 3.9 ± 1.9
Medium HDL Particles (μmol/L) 8.5 ± 1.6 8.8 ± 1.9
Small HDL Particles (μmol/L) 13.8 ± 1.4 13.9 ± 1.5
HDL Particle Size (nm) 9.3 ± 1.1† 9.0 ± 1.1
Data are presented as mean ± SD, geometric mean ± SD for nonnormally
distributed variables, or frequency (percent)
†Significantly different (P < 0.05) as compared to controls using mixed models
HAQ-DI Health Assessment Questionnaire Disability Index, DASESR-28 Disease
activity score with 28 joint count using erythrocyte sedimentation rate, hsCRP
High sensitivity C-reactive protein, LDL Low density lipoprotein, HDL High
density lipoprotein, RA Rheumatoid arthritis
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or lipid parameters were associated with abdominal sub-
cutaneous adiposity.
Lipoprotein associations with physical activity in RA
Since HDL profiles appeared more related to pain and
disability than disease activity or inflammation, we hy-
pothesized that in RA, HDL profiles might be impacted
by lack of physical activity. In fact, more basal activity
time (minimal physical activity) was associated with
fewer total HDL-P and small HDL-P (Fig. 1), more large
HDL-P, and larger mean HDL-size (Table 2; P < 0.05 for
all). On the other hand, more exercise time was associ-
ated with a profile that shifted toward more small HDL-
P, fewer large HDL-P, and reduced mean HDL-size
(Table 2; P < 0.05 for all). Further, the relationship be-
tween basal activity and small HDL-P was independent
of exercise time and together, both accounted for 29% of
the variance in small HDL-P (model P < 0.002; Pbasal activity
time < 0.005; Pexercise time < 0.28).
For LDL, more basal activity and less exercise time
were associated with fewer small LDL-P (Fig. 1 and
Table 2; P < 0.05 for both) and a larger mean LDL-size
(Table 2; P < 0.05 for both). More basal activity time
remained independently and inversely related to small
LDL-P concentrations even when controlling for exer-
cise time (model P < 0.01; model R2 = 0.23; Pbasal activity
time < 0.01; Pexercise time = 0.37).
To determine whether the effects of minimal physical
activity and exercise time on lipoproteins were impacted
by age, gender, inflammation and adiposity, we performed
adjusted linear regression analyses. Analyses targeted
small LDL-P and small HDL-P because these were most
strongly related to the physical activity measures. Simi-
larly, basal activity or minimal physical activity time was
included as the physical activity measure because it had
shown stronger bivariate relationships. Basal activity was
inversely associated with small HDL-P (P = 0.001) and this
association remained significant and unattenuated even
after adjusting for age, gender, disability, pain, TNFα, IL-6,
BMI and abdominal visceral adiposity (P < 0.05) (Table 3).
Pain showed a significant inverse association with small
HDL-P in a model that contained basal activity, age,
Table 2 Relationships between lipoprotein parameters and various measures in persons with RA (n = 50)
Total
LDL-P
Large
LDL-P
Small
LDL-P
LDL
Size
LDL-C Total
HDL-P
Large
HDL-P
Medium
HDL-P
Small
HDL-P
HDL
Size
HDL-C
Disease Activity
Disability (HAQ-DI) −0.10 0.11 −0.19 0.10 −0.10 −0.25 0.10 −0.02 −0.37† 0.20 −0.10
Pain (VAS) (mm) −0.15 −0.06 −0.13 −0.06 −0.07 −0.32† −0.03 0.02 −0.42‡ 0.11 −0.20
Disease activity (DASESR-28) 0.00 0.08 0.05 −0.04 −0.03 −0.20 −0.02 0.03 −0.26 0.06 −0.19
ESR (mm/h) −0.08 −0.03 0.06 −0.10 −0.13 −0.02 −0.05 0.12 −0.08 −0.01 −0.09
hsCRP (mg/L) −0.05 −0.14 0.14 −0.24 −0.04 −0.22 −0.12 −0.04 −0.07 −0.08 −0.18
IL-1β (pg/ml) −0.15 −0.14 0.00 −0.12 −0.02 −0.02 −0.11 0.19 −0.15 −0.04 −0.00
IL-6 (pg/ml) −0.07 −0.17 0.09 −0.31† −0.27 −0.12 −0.06 −0.07 0.01 −0.12 −0.21
IL-18 (pg/ml) 0.16 −0.23 0.26 −0.33† −0.23 −0.05 −0.26 −0.08 0.19 −0.26 −0.03
TNF-α (pg/ml) 0.26 −0.07 0.23 −0.28† −0.30† −0.26 −0.23 −0.31† 0.14 −0.24 −0.04
Body Composition
Body mass index (kg/m2) 0.37† 0.01 0.33† −0.08 0.32† −0.14 −0.38† −0.23 0.24 −0.32† −0.22
Waist circumference (cm) 0.39† −0.03 0.37† −0.14 0.23 −0.13 −0.44‡ −0.22 0.29† −0.42‡ −0.29†
Abdominal visceral adiposity (cm2) 0.47‡ 0.13 0.32† −0.07 0.38† −0.04 −0.41‡ −0.05 0.21 −0.39† −0.17
Abdominal subcutaneous adiposity (cm2) 0.20 0.01 0.16 0.05 0.17 −0.07 −0.24 −0.14 0.14 −0.20 −0.08
Insulin Action
Insulin sensitivity (×10−5 min1/[pmol/L]) −0.28 0.17 −0.30 0.32† 0.18 0.39† 0.25 0.24 0.12 0.20 0.31†
HOMA-IR 0.37† −0.26 0.53‡ −0.53‡ 0.06 −0.22 −0.54‡ −0.24 0.24 −0.53‡ −0.51‡
Fasting insulin (mU/L) 0.34† −0.25 0.43‡ −0.45‡ 0.30† −0.29 −0.48‡ −0.31† 0.18 −0.46‡ −0.47‡
Physical Activity (n = 41)
Basal activity (% min) −0.29 0.19 −0.48‡ 0.33† −0.12 −0.31† 0.37† −0.02 −0.52‡ 0.43‡ 0.23
Exercise (% min) 0.18 −0.24 0.41† −0.32† −0.02 0.22 −0.37† 0.05 0.37† −0.43‡ −0.30
HAQ-DI Health Assessment Questionnaire Disability Index, VAS visual analogue scale, DASESR-28 Disease activity score with 28 joint count using erythrocyte
sedimentation rate (ESR), hsCRP High sensitivity C-reactive protein, HOMA-IR Homeostatic model assessment of insulin resistance, LDL-P Low density lipoprotein
particles, LDL-C Low density lipoprotein cholesterol, HDL-P High density lipoprotein particles, HDL-C High density lipoprotein cholesterol, RA Rheumatoid arthritis
Data are shown as Spearman correlation coefficients (r). †0.005 < P < 0.05 ‡P ≤ 0.005
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Fig. 1 Relationship between physical activity and RA-associated lipoprotein particles. a Basal activity and small LDL-particles. b Basal activity and
small HDL-particles. Physical activity was measured with seven days of accelerometry. Basal activity was defined as physical activity expending less
than one metabolic equivalent. Lipoprotein subclasses were measured by NMR
Table 3 Multivariable linear regression analysis demonstrating relationship of basal activity with small HDL-P
Small HDL-P (Log μmol/L) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
β p value β p value β p value β p value β p value β p value
Basal activity (% min/week) −0.013 0.001 −0.013 0.003 −0.011 0.01 −0.012 0.004 −0.012 0.005 −0.009 0.046
Age (yrs) −0.002 0.37 −0.003 0.10 −0.001 0.44 −0.003 0.11 −0.004 0.07
Gender −0.020 0.71 −0.064 0.27 −0.008 0.88 −0.037 0.50 −0.055 0.39
Disability (HAQ-DI) 0.016 0.74 −0.007 0.90
Pain (VAS) −0.002 0.03 −0.002 0.15
TNFα (pg/ml) 0.001 0.21 0.0007 0.38
IL-6 (pg/ml) −0.002 0.33 0.0003 0.86
BMI (kg/m2) 0.006 0.12 0.006 0.16
Visceral adiposity (cm2) 0.0003 0.48 0.0003 0.44
β: Partial regression coefficient
Model 1 = unadjusted linear regression model
Model 2 = adjusted for age and gender (Parameter estimates are for women; men = 0)
Model 3 = adjusted for age, gender, disability and pain
Model 4 = adjusted for age, gender, TNFα and IL-6
Model 5 = adjusted for age, gender, BMI and visceral adiposity
Model 6 = adjusted for age, gender, disability, pain, TNFα, IL-6, BMI and visceral adiposity
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gender and disability (P < 0.05) (Table 3). However, the as-
sociation of pain with small HDL-P was attenuated after
further adjustment for TNFα, IL-6, BMI and abdominal
visceral adiposity (P = 0.15). None of the other parameters
showed a significant association with small HDL-P
(Table 3). Basal activity was also inversely associated with
small LDL-P (P = 0.002) and this association remained
significant and unattenuated even after adjusting for age,
gender, disability, pain, TNFα, IL-6, BMI and abdominal
visceral adiposity (P < 0.05) (Table 4). Age and gender
were also inversely associated with small LDL-P after
adjusting for age, gender, disability, pain, TNFα, IL-6, BMI
and abdominal visceral adiposity (P < 0.05). However,
these associations were not consistently significant in
every model tested (Table 4).
Discussion
Similar to prior reports, we found that compared to
controls, subjects with RA had lower NMR-measured
concentrations of total and small LDL-particles, yet lar-
ger LDL- and HDL-particle sizes [10, 20]. There were
trends toward fewer small particles and/or more large
particles in both LDL and HDL lipoprotein classes.
Here, we expanded the current knowledge regarding
RA lipoprotein profiles and demonstrate associations
for each of physical activity, inflammation, and trad-
itional cardiometabolic risk factors. Most similar to the
RA lipoprotein profile, more time spent in basal activity
(minimal physical activity) and less spent in exercise
were associated with fewer small LDL and small HDL
particles.
To our knowledge, this is the first report suggesting
that the unfavorable HDL profile (fewer small particles)
associated with RA may result in large part from
minimal physical activity. Among those with RA, basal
activity was associated with less small HDL-, fewer total
HDL-particles, and an increased mean HDL-size. Add-
itionally, time spent in exercise had the inverse effect on
HDL profiles. Further, fewer small HDL concentrations
were associated with pain and disability, while there
were no HDL associations with cytokines. In persons
without RA, exercise is known to exert beneficial effects
on HDL-particles [15, 21, 22]. However, these exercise
effects are due primarily to increases in large and
medium, rather than small, HDL-particles [15, 23].
Thus, our observed effects of inactivity and exercise on
small HDL may be unique to those with active RA—and
perhaps other inflammatory diseases.
NMR-measured HDL parameters in persons with RA
were associated with traditional cardiometabolic risks of
adiposity and glucose homeostasis. Most consistently,
increased adiposity was associated with fewer large HDL-
particles. This reduction in large HDL-particles appears
distinct from, and potentially additive with, the
inactivity-associated reductions in small HDL-particles,
which together may culminate in significant pro-
atherogenic effects.
These findings are consistent with recognition that
HDL-particles have heterogeneous functions and com-
position [12, 24]. Typically, both large and small HDL-
particles participate in reverse cholesterol transport,
the major driver of the inverse relationship between
HDL-particles and cardiometabolic disease [12]. Also,
HDL-particles exert vasodilatory and anti-thrombotic
effects, primarily mediated by large HDL-particles [24].
Additionally, protein-rich small HDL mediate anti-
inflammatory and anti-oxidative functions via transport of
proteins with anti-inflammatory and immunomodulatory
Table 4 Multivariable linear regression analysis demonstrating relationship of basal activity with small LDL-P
Small LDL-P (Log μmol/L) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
β p value β p value β p value β p value β p value β p value
Basal activity (% min/week) −0.026 0.002 −0.023 0.01 −0.022 0.02 −0.023 0.01 −0.021 0.02 −0.020 0.03
Age (yrs) −0.007 0.06 −0.010 0.02 −0.007 0.04 −0.008 0.04 −0.011 0.01
Gender −0.172 0.12 −0.257 0.04 −0.185 0.10 −0.217 0.07 −0.376 0.01
Disability (HAQ-DI) −0.012 0.90 0.055 0.66
Pain (VAS) −0.002 0.24 −0.004 0.13
TNFα (pg/ml) −0.001 0.69 −0.002 0.18
IL-6 (pg/ml) −0.005 0.14 −0.006 0.15
BMI (kg/m2) 0.013 0.10 0.013 0.13
Visceral adiposity (cm2) 0.0001 0.95 −0.001 0.40
β: Partial regression coefficient
Model 1 = unadjusted linear regression model
Model 2 = adjusted for age and gender (Parameter estimates are for women; men = 0)
Model 3 = adjusted for age, gender, disability and pain
Model 4 = adjusted for age, gender, TNFα and IL-6
Model 5 = adjusted for age, gender, BMI and visceral adiposity
Model 6 = adjusted for age, gender, disability, pain, TNFα, IL-6, BMI and visceral adiposity
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functions [24]. However, in the setting of increased in-
flammation, such as in active RA, such proteins are re-
placed with pro-inflammatory and acute phase proteins
[12, 14]. Furthermore, HDL transport of inflammatory
proteins occurs at the expense of apolipoproteins
resulting in less HDL-mediated reverse cholesterol
transport [13]. Exacerbating these issues, inflammation
increases HDL-particle catabolism and renal clearance
resulting in fewer HDL-particles [12, 24].
The relationship between LDL-particles and RA is just
as complex. As compared to controls, patients with RA
had fewer total and small LDL-particles, resulting in a
larger mean LDL-size. The association of excess CVD
with lower LDL concentrations has been described as
“the lipid paradox of RA;” fewer small LDL particles
continues to support a paradoxical relationship. RA-
associated inflammation increases cholesterol catabolism
such that small, cholesteryl ester (CE)-laden particles,
transfer CE to the liver at increased rates, resulting in
fewer small CE containing LDL and lower LDL-C [13].
However, in our RA cohort, increased inflammatory
cytokines were not associated with fewer small LDL-
particles and larger mean LDL-sizes; instead, they were
associated with smaller mean LDL-particle sizes. Thus, it
appears that the RA-associated LDL profile is not medi-
ated entirely by inflammation. Additionally, as trad-
itional cardiometabolic risk factors were associated with
more total and small LDL-particles, it appears the RA-
associated LDL profile (fewer total and small LDL) is
not mediated by adiposity or insulin resistance.
Interestingly, both less time exercising and more
basal or minimal physical activity were associated with
fewer small LDL-particles and larger mean LDL-sizes.
Further, the effects of minimal physical activity on
LDL-particles were independent of exercise time. It
may be that less physically active patients are those
with higher disease activity and concomitantly have the
typical dyslipidemia that is observed in active rheumatic
disease (i.e., decreased small LDL- and HDL-particles
and normal total and LDL-cholesterol levels). However,
rather than larger LDL sizes, smaller LDL sizes were asso-
ciated with increased concentrations of several inflamma-
tory cytokines. Consequently, rather than concluding that
physical activity worsens LDL profiles, it appears more
likely that patients who were more active tended to
have a reversal of the typical inflammatory dyslipidemia
that is observed in RA patients [10, 13, 14]. These lipo-
protein changes may be mediated by anti-inflammatory
effects of exercise [25–29]. Similarly, lipoprotein
changes are observed in RA patients who have been
treated with anti-TNF-alpha agents, IL-6 receptor an-
tagonists and JAK inhibitors [13, 14, 30, 31]. Concomi-
tant HDL function improvements suggest these shifts
are atheroprotective [13, 31].
We recognize that this study has limitations. The
cross-sectional nature makes it impossible to determine
causality. A small number of subjects was used for this
study, therefore the results may be considered prelimin-
ary and larger studies are needed to confirm these re-
sults. Also, we recognize that multiple statistical analyses
were performed without correction for multiple testing.
However, we focused on associations that were consist-
ent across multiple similar, yet independent, measures,
reported strengths of associations and ranges of signifi-
cance such that the reader can consider these in inter-
pretation of the findings.
Conclusions
In this RA cohort with mild to moderate disease activity,
we found lipoprotein profiles similar to those previously
reported: there were fewer total and small LDL particles
in the setting of larger HDL particles, consistent with
the RA lipoprotein profile. We identified intriguing asso-
ciations for basal or minimal physical activity and exer-
cise time with lipoprotein parameters suggestive that a
large part of the RA lipid profile is mediated by lack of
physical activity. These findings call for intervention
studies in RA evaluating the impact of reduced seden-
tary time, in the setting of increased disability and pain,
on lipoproteins and overall cardiometabolic health; they
also call for research designed to understand the under-
lying mechanisms of these observed effects.
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